From precision medicine to cancer care through the immunome: Highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014

ecancermedicalscience

Volumn 8, Issue , 2014, Pages

  Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Conference report; ESMO 2014

Indexed keywords

ACCURACY; ARTICLE; BREAST CANCER; GASTROINTESTINAL TUMOR; GYNECOLOGIC CANCER; HUMAN; IMMUNITY; IMMUNOME; LUNG CANCER; MEDICAL SOCIETY; MELANOMA; ONCOLOGIST; ONCOLOGY; PROSTATE CANCER; SPAIN; UROGENITAL TRACT TUMOR;

EID: 84908256354     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.472     Document Type: Article

References (28)

1. Ding L et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft Nature 464(7291) 999-1005 DOI: 10.1038/nature08989 PMID: 20393555 PMCID: 2872544
2. Vogelstein B and Kinzler KW (2004) Cancer genes and the pathways they control Nat Med 789-99 DOI: 10.1038/nm1087 PMID: 15286780
3. Giovanni Parmigiani et al (2009) Design and analysis issues in genome-wide somatic mutation studies of cancer Genomics 93(1) 17-21
4. Douglas Hanahan and Robert A Weinberg (2011) Hallmarks of Cancer The Next Generation Cell 144(5) 646-74 DOI: 10.1016/j.cell.2011.02.013
5. Fabrice Andre, Suzette Delaloge, and Jean-Charles Soria (2011) Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection? J Clin Oncol 29(10) 1236-8 DOI: 10.1200/JCO.2010.31.6877
6. Swain SM et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14(6) 461-71 DOI: 10.1016/S1470-2045(13)70130-X PMID: 23602601 PMCID: 4076842
7. Gligorov J (2014) Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Lancet Oncol pii: S1470-2045(14) 70444-9 DOI: 10.1016/S1470-2045(14)70444-9 PMID: 25273343
8. Von Minckwitz G et al (2014) Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial Lancet Oncol 15(11) 1269-78 DOI: 10.1016/S1470-2045(14)70439-5 PMID: 25273342
9. M Arnedos et al (2014) Genomic and immune characterization of metastatic breast cancer: an ancillary study of the SAFIR01 and MOSCATO trials Abstract 351O Ann Oncol 25 (Supplement 4)
10. H Bonnefoi et al Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab or both followed by an anthracycline based chemotherapy in HER2 positive breast cancer: Results of the randomized phase II EORTC 10054 study Abstract 253O Ann Oncol 25 (Supplement 4)
11. V Guarneri (2014) Activity of neoadjuvant lapatinib plus trastuzumab for early breast cancer according to PIK3Ca mutations: pathological complete response rate in the CHERLOB study and pooled analysis of randomized trials Abstract 254O Ann Oncol 25 (Supplement 4)
12. C Sweeney (2014) Chemohormonal therapy vs hormonal therapy for hormone naïve high volume newly metastatic prostate cancer: ECOG LED phase III randomized trial Abstract 756O Ann Oncol 25 (Supplement 4)
13. CJ Ryan et al (2014) Final overall survival analysis of COU-AA-302, a randomized phase III study of abiraterone acetate in metastatic castration resistant prostate cancer with or without prior chemotherapy Abstract 753O Ann Oncol 25 (Supplement 4)
14. Antonarakis ES et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371(11) 1028-38 PMID: 25184630
15. DF McDermott (2014) Immune correlated and long term follow up pf a phase IA study of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma Abstract 809O Ann Oncol 25 (Supplement 4)
16. D Sargent et al (2014) CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC) Abstract 609TiP Ann Oncol 25 (Supplement 4)
17. RS Midgley (2014) Final results from QUASAR2, a multicenter interational tandomized phase III trial of capecitabina +/- bevacizumab in the adjuvant setting of stage II/III colorectal cancer LBA12 Ann Oncol 25 (Supplement 4)
18. K Muro (2014) A phase IB study of pembrolizumab (MK-3475) in patients with advanced gastric cancer LBA15 Ann Oncol 25 (Supplement 4)
19. KS Tewari (2014) Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: A NRG Oncology - Gynecologic Oncology Group Study LBA26 Ann Oncol 25 (Supplement 4)
20. R Kristeleit et al (2014) A phase I/II study of oral rucaparib: updated phase I and preliminary phase II results. 882PD Ann Oncol 25 (Supplement 4)
21. AMM Eggermont et al Efficacy, safety and Quality of Life data from EORTC 18071 phase III trial of ipilimumab versus placebo after complete resection of stage III melanoma 1087O Ann Oncol 25 (Supplement 4)
22. Long GV (2014) Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma N Engl J Med [Epub ahead of print] DOI: 10.1056/NEJMoa1406037 PMID: 25265492 PMCID: 4010094
23. James Larkin (2014) Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma N Engl J Med [Epub ahead of print]
24. TSK Mok et al Gefitinib/chemotherapy vs chemotherapy in EGFR mutation positive non small cell lung cancer after progression on first line gefitinib: the phase III, randomized IMPRESS study LBA2 Ann Oncol 25 (Supplement 4)
25. JF Vansteenkiste (2014) MAGRIT, a double blind, randomized, placebo-controlled phase III study to assess the efficacy of MAGE-A3 plus AS15 cancer immunotherapeutics in patients with resected MAGE A3 positive non small cell lung cancer. Abstract: 1173O Ann Oncol 25 (Supplement 4)
26. J Temel et al Anamorelin for the treatment of cancer anorexia-cachexia in non small cell lung cancer: results from the phase III studies ROMANA 1 and 2 Abstract 1483O Ann Oncol 25 (Supplement 4)
27. Meric-Bernstam F and Mills GB (2012) Overcoming implementation challenges of personalized cancer therapy Nature Rev Clinical Oncol 9 542-8
28. Curigliano G (2012) New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance Cancer Treatment Rev 38 303-10